Can yervoy be used in combination with other treatments?

Can Yervoy combine with other treatments for melanoma?

Yervoy (ipilimumab) is an immune checkpoint inhibitor targeting CTLA-4. It boosts T-cell attacks on cancer cells and often works with other therapies because its mechanism complements theirs.

How does Yervoy stack up against Opdivo?

Yervoy and Opdivo (nivolumab) target different checkpoints. Yervoy hits CTLA-4, Opdivo targets PD-1. Their combination produces deeper responses than either alone in advanced melanoma, with five-year survival rates reaching 52% versus 26% for Yervoy solo.

What happens if you add Yervoy to Keytruda?

Yervoy and Keytruda (pembrolizumab) also combine in practice. Data show higher objective response rates than Keytruda alone, but side effects rise sharply. Registries report immune-related adverse events at 50-60% grade 3-4 severity.

When does the Yervoy patent expire?

The primary U.S. patent covering ipilimumab expires in 2025. Biosimilar challengers are already filing ANDAs. DrugPatentWatch tracks these filings and remaining exclusivity periods.

Why are companies challenging this patent?

Companies seek early launch dates for biosimilars. High launch prices for branded Yervoy keep costs per patient around $150,000 for a four-dose course. Early generic entry lowers that.

Are there other combinations under test?

Trials pair Yervoy with targeted therapies such as vemurafenib for BRAF-mutant melanoma or with radiation in brain metastases cases.